Blog Business Entertainment Environment Health Latest News News Analysis Opinion Science Sports Technology Videos World
UK Approves Mounjaro, A New Weight Loss Prescription

A diabetes medication known as "Mounjaro" or tirzepatide has received approval in the UK for the treatment of obesity,  says BBC. 

This medication induces a sensation of fullness, leading to reduced food intake.

BBC reports that in clinical trials, people taking the medication have lost, on average, a fifth of their body weight, and the UK's regulatory body has deemed it safe and effective enough to be prescribed. 

However, it is not yet recommended by the National Health Service (NHS).

Although, the NHS uses this medication for diabetes treatment. The National Institute for Health and Care Excellence (NICE), which is responsible for the healthcare spending evaluation, is currently assessing its usage for obesity and will provide its findings in March 2024. 

Wegovy, a medication for obesity, is similar to Mounjaro and both are available as pre-filled injection pens for patients to administer themselves by injecting the dose under the skin of their stomach or thigh.

These medications can assist people in losing a substantial amount of weight. However, in research, many users tend to regain weight after discontinuing the treatment. 

Weight loss drugs can carry certain risks, and there's an investigation into their potential association with the risk of suicide. It is also important to note that these medicines may have side effects, with the most common being nausea, diarrhea, vomiting, and constipation.

Experts caution that Mounjaro may affect how well the contraceptive pill works. Women who are on it should consider using additional extra contraception, such as condoms or switching to a non-oral contraceptive method for four weeks after starting Mounjaro and for four weeks after each increase in dose.

Wegovy shots, which contain a drug called semaglutide, are being offered by some specialist NHS weight-loss management services, as well as some private clinics. There is a plan for general practitioners (GPs) to offer it too.

Some stores on High Street are prescribing and selling it too, although stocks are limited.

As more doses become available, it could help tens of thousands of patients in England, the NHS says.

In the future, Mounjaro might be added to the list of possible NHS treatments too.

The UK's drugs regulator, the MHRA, says it can be used by adults who are obese or those who are overweight and have weight-related health problems such as high blood pressure.

Health and Social Care Secretary Steve Barclay said: "Although further approvals are needed to use this in the NHS, Mounjaro has the potential to help thousands of people living with obesity and support those suffering from weight-related illnesses - if used alongside diet and physical activity. Tackling obesity could help cut waiting lists and save the NHS billions of pounds."


Share This Post On

Tags: #ObesityMedication #WeightLossJabs #NHSInnovations #MounjaroTreatment #HealthcareUpdates


Leave a comment

You need to login to leave a comment. Log-in is a Global Media House Initiative by Socialnetic Infotainment Private Limited.

TheSocialTalks was founded in 2020 as an alternative to mainstream media which is fraught with misinformation, disinformation and propaganda. We have a strong dedication to publishing authentic news that abides by the principles and ethics of journalism. We are an organisation driven by a passion for truth and justice in society.

Our team of journalists and editors from all over the world work relentlessly to deliver real stories affecting our society. To keep our operations running, We need sponsors and subscribers to our news portal. Kindly sponsor or subscribe to make it possible for us to give free access to our portal and it will help writers and our cause. It will go a long way in running our operations and publishing real news and stories about issues affecting us.

Your contributions help us to expand our organisation, making our news accessible to more everyone and deepening our impact on the media.

Support fearless and fair journalism today.